鼠李糖乳杆菌
结肠炎
肠道菌群
炎症性肠病
炎症
溃疡性结肠炎
免疫学
医学
乳酸菌
微生物学
生物
疾病
细菌
内科学
遗传学
作者
Lingjun Tong,Xinyi Zhang,Haining Hao,Qiqi Liu,Zihan Zhou,Xi Liang,Tongjie Liu,Pimin Gong,Lanwei Zhang,Zhengyuan Zhai,Yanling Hao,Huaxi Yi
出处
期刊:Nutrients
[MDPI AG]
日期:2021-09-23
卷期号:13 (10): 3319-3319
被引量:90
摘要
Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease. Probiotics have a potential beneficial effect on the prevention of UC onset and relapse in clinical trials. Lactobacillus rhamnosus GG (L. rhamnosus GG) have shown clinical benefits on UC patients, however, the precise mechanisms are unknown. The aim of this study is to explore the effect of extracellular vesicles released from L. rhamnosus GG (LGG-EVs) on dextran sulfate sodium (DSS)-induced colitis and propose the underlying mechanism of LGG-EVs for protecting against colitis. The results showed that LGG-EVs could prevent colonic tissue damage and shortening of the colon (p < 0.01), and ameliorate intestinal inflammation by inhibiting TLR4-NF-κB-NLRP3 axis activation. Consistently, the pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-2) were suppressed effectively upon LGG-EVs treatment (p < 0.05). The 16S rRNA sequencing showed that LGG-EVs administration could reshape the gut microbiota in DSS-induced colitis mice, which further alters the metabolism pathways of gut microbiota. These findings propose a novel perspective of L. rhamnosus GG in attenuating inflammation mediated by extracellular vesicles and offer consideration for developing oral gavage of LGG-EVs for colitis therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI